Dr. John Cush RheumNow
2 years 3 months ago
Finnish study of 331 systemic sclerosis (SSc) pts found that SSc is the major cause of death in diffuse & limited SSc. Among 91 deaths, the 5 & 10 year survival was 88% and 80%. Most common cause death was SSc (n=35)& ILD (13). https://t.co/m30CoAdsMN https://t.co/Ms9LN7eAUK
Dr. John Cush RheumNow
2 years 3 months ago
Swap or Cycle? Study OP0081 show after failure to a first TNFi in patients with axSpA, the drug retention rate was higher in the cycle strategy compared to the swap (IL-17i) strategy. No difference in the disease activity between cycle and swap strategy #EULAR2024
Dr. John Cush RheumNow
2 years 3 months ago
RT @yuz6yusof #EULAR2024 OP0043 Data from UK BILAG-BR registry showed in n>100 patients w neuropsychiatric #lupus (NPSLE), over 2/3 improved with rituximab. NPSLE tended to occur with other #SLE features and with high level of organ damage @RheumNow https://t.co/45OM0PLtjM
Dr. John Cush RheumNow
2 years 3 months ago
Study of 387 lupus nephritis pts found pulmonary HTN in 15%. An increased risk of PH was seen w/ eGFR <30, and w/ low Hgb, low triglycerides. PH was independently associated with a higher risk (HR ~ 2.0) of all-cause mortality and adverse renal outcomes https://t.co/hdLjOZc9TI https://t.co/60lhdo93lm
A study from the University of British Columbia has evaluated the trajectories of hydroxychloroquine (HCQ) use in patients with incident RA and SLE between1997 and 2021, and identified factors associated with high adherence. From a total of 27,510 RA/SLE patients taking antimalarial therapy (23,997 RA and 3,513 SLE), they identified four groups of antimalarial adherence trajectories; ordered from worse to better:
Trials are underway evaluating the potential benefits of JAK inhibitors (JAKi) in giant cell arteritis (GCA) patients who are refractory to standards of care. An observational real-world analysis of a small worldwide cohort suggests the utility of JAKi in GCA.
Dr. John Cush RheumNow
2 years 3 months ago
Planetary Health in Rheumatology
Dr. Antoni Chan interviews Dr. Nelly Ziade about her session Planetary Health, presented at Eular 2024 in Vienna, Austria.
https://t.co/gBkwyO1dWQ https://t.co/VvGqwi6tlJ
Dr. John Cush RheumNow
2 years 3 months ago
Study of 2,974 SLE pts taking hydroxychloroquine (HCQ) found 584 w/ ≥1 hospitalization for SLE. Taking Lower doses of HCQ (≤5 mg/kg/d) or <400 mg/d were assoc w/ increased hospitalizations for active SLE (adjusted OR 4.20 & aOR 3.39, respectively) https://t.co/xXLiGFoU3L https://t.co/Sy36aOG81Y
Dr. John Cush RheumNow
2 years 3 months ago
Abatacept Misses on Shingrix Response
Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria.
https://t.co/rNOARWzEcI https://t.co/xebXgsouta
Dr. John Cush RheumNow
2 years 3 months ago
Top 10 Drug companies (revenue)
10 Regeneron $12.2b
9 Vertex $8.9b
8 Amgen $26.3b
7 Gilead $27.3b
6 Lilly $28.5b
5 BMS $46.2b
4 Merck $59.3b
3 AbbVie $58.1b
2 J&J $94.9b
1 Pfizer $100.3b https://t.co/GNlGToGcb1 https://t.co/OWyVUBzeO6
Dr. John Cush RheumNow
2 years 3 months ago
JAMA: 3 prospective cohort studies in USA show that multivitamin use by 390 124 healthy adults did not alter mortality risk (HR, 1.04; 95% CI, 1.02-1.07) https://t.co/VDxrI5Bskw https://t.co/o9wdITR0UT
Dr. John Cush RheumNow
2 years 3 months ago
Is Rheumatoid Arthritis Preventable?
Many conventional synthetic, biological, biosimilar, and targeted synthetic disease-modifying anti-rheumatic drugs are currently commercially available for the effective treatment of rheumatoid arthritis.
https://t.co/KmAFGwx414 https://t.co/ag5W9j9Kky
This meta-analysis of psoriasis treatments shows that biologic therapies may be less effective in certain psoriasis (PSO) patients, particularly those who are older, smokers, with higher BMI an prior exposure to biologics.
